Collaboration and Licensing Revenue - Additional Information (Details) - USD ($)	1 Months Ended		5 Months Ended
	Jun. 30, 2016	Mar. 31, 2016	May 31, 2016
Exotech Bio, Inc.
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement		90 days
Exotech Bio, Inc. | Maximum
Collaboration and Licensing Agreements [Line Items]
Milestone payments required upon successful achievement, per product		$ 52,500,000
Exotech Bio, Inc. | Upfront | Upfront and Milestone Payments
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value		$ 5,000,000
Relieve Genetics, Inc.
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement		90 days
Relieve Genetics, Inc. | Maximum
Collaboration and Licensing Agreements [Line Items]
Milestone payments required upon successful achievement, per product		$ 52,500,000
Relieve Genetics, Inc. | Upfront | Upfront and Milestone Payments
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value		$ 4,333,000
Intrexon T1D Partners, LLC
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement		90 days
Intrexon T1D Partners, LLC | Upfront | Upfront and Milestone Payments
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value		$ 10,000,000
AD Skincare, Inc.
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
AD Skincare, Inc. | Maximum
Collaboration and Licensing Agreements [Line Items]
Milestone payments required upon successful achievement, per product	$ 2,000,000
Maximum milestone payments required upon successful achievement, one-time	17,000,000
AD Skincare, Inc. | Upfront | Upfront and Milestone Payments
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value	$ 4,333,000
ZIOPHARM Oncology, Inc.
Collaboration and Licensing Agreements [Line Items]
Royalty rate as a percentage of net profit	20.00%		50.00%
ZIOPHARM Oncology, Inc. | Other Contractual Payments | Upfront and Milestone Payments
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value	$ 120,000,000
Collaborative arrangement consideration received, number of preferred shares	100,000